The Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Department of Diabetes and Endocrinology, The Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Clin Endocrinol (Oxf). 2019 Feb;90(2):328-333. doi: 10.1111/cen.13892. Epub 2018 Nov 27.
Patients with hyperthyroidism lacking autoimmune features but showing diffuse uptake on thyroid scintigram can have either Graves' disease or germline activating TSH receptor (TSHR) mutation. It is important to identify patients with activating TSHR mutation due to treatment implication, but the overlapping clinical features with Graves' disease make it difficult to discriminate these two conditions without genetic testing. Our study aimed to assess the potential of systematic TSHR mutation screening in adults with hyperthyroidism, showing diffuse uptake on thyroid scintigraphy but absence of TSH receptor antibodies (TRAb) and clinical signs of autoimmunity.
A cross-sectional study of Caucasian adults with hyperthyroidism, managed at three endocrine centres in the South West, UK, from January 2006 to April 2017.
We recruited 78 adult Caucasian patients with hyperthyroidism showing diffuse uptake on Tc-pertechnetate thyroid scintigraphy but without TRAb and other autoimmune clinical features of Graves' disease (such as thyroid-associated ophthalmopathy or dermopathy). Genomic DNA of these patients was analysed for variants in the TSHR gene.
Genetic analysis identified 11 patients with four variants in TSHR [p.(Glu34Lys), p.(Asp36His), p.(Pro52Thr) and p.(Ile334Thr)]. None of these variants were pathogenic according to the American College of Medical Genetics and Genomics guideline.
Activating TSHR mutations are a rare cause of nonautoimmune adult hyperthyroidism. Our study does not support the routine genetic testing in adult patients with hyperthyroidism showing diffuse uptake on scintigraphy but negative TRAb and lacking extrathyroidal manifestations of Graves' disease.
缺乏自身免疫特征但甲状腺闪烁显像显示弥漫性摄取的甲状腺功能亢进症患者可能患有格雷夫斯病或种系激活 TSH 受体(TSHR)突变。由于治疗意义,识别出具有 TSHR 激活突变的患者非常重要,但与格雷夫斯病的重叠临床特征使得在没有遗传检测的情况下难以区分这两种情况。我们的研究旨在评估在甲状腺闪烁显像显示弥漫性摄取但缺乏 TSH 受体抗体(TRAb)和自身免疫临床体征的甲状腺功能亢进症成人中进行系统 TSHR 突变筛查的潜力。
这是一项在英国西南部的三个内分泌中心于 2006 年 1 月至 2017 年 4 月期间管理的甲状腺功能亢进症成人的横断面研究。
我们招募了 78 名表现为甲状腺闪烁显像显示弥漫性摄取但无 TRAb 和其他格雷夫斯病自身免疫临床特征(如甲状腺相关眼病或皮肤病)的甲状腺功能亢进症的成年白种人患者。对这些患者的基因组 DNA 进行 TSHR 基因变异分析。
基因分析确定了 11 名患者存在 TSHR 中的四个变异 [p.(Glu34Lys)、p.(Asp36His)、p.(Pro52Thr) 和 p.(Ile334Thr)]。根据美国医学遗传学与基因组学学院的指南,这些变异均无致病性。
激活的 TSHR 突变是成人非自身免疫性甲状腺功能亢进症的罕见原因。我们的研究不支持在甲状腺闪烁显像显示弥漫性摄取但 TRAb 阴性且缺乏格雷夫斯病的甲状腺外表现的甲状腺功能亢进症成年患者中进行常规基因检测。